沃森生物：子公司双价HPV疫苗目前生产、批签发申报和销售工作均正常开展

Core Viewpoint - Watson Bio (300142) is actively managing the production, approval, and sales of its bivalent HPV vaccine through its subsidiary Yuxi Zerun Biotechnology Co., Ltd, ensuring product availability and compliance with policy changes [1] Group 1 - The bivalent HPV vaccine's production and sales processes are currently operating normally [1] - The company is monitoring policy adjustments and is prepared to take proactive measures to respond [1] - The goal is to ensure product supply and benefit a wider audience [1]